Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model.

Gene expression - 18 May 2018

Zhan Na, Michael Adeola Adebayo, Wu Kaiyuan, Zeng Gang, Bell Aaron, Tao Junyan, Monga Satdarshan P

Abstract excerpt

Simultaneous mutations in CTNNB1 and activation of c-MET occur in 9%-12.5% of patients with hepatocellular carcinoma (HCC). Coexpression of c-MET-V5 and mutant β-catenin-Myc in mouse liver by sleeping beauty transposon/transposase and hydrodynamic tail vein injection (SB-HTVI) led to the development of HCC with 70% molecular identity to the clinical subset. Using this model, we investigated the effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Share to Pyridazines

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 29409568
DOI: 10.3727/105221618X15174108894682
PMCID: PMC5954626

Genes

MET
CTNNB1
PCNA
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model.PMID 29409568Read ↗

Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point‐mutant β‐cateninSemantic proximity Read ↗

Targeting β‐catenin in hepatocellular cancers induced by coexpression of mutant β‐catenin and K‐Ras in miceSemantic proximity Read ↗

Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in miceSemantic proximity Read ↗

Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinomaSemantic proximity Read ↗

β‐catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β‐catenin and METSemantic proximity Read ↗

Distinct pathways of genomic progression to benign and malignant tumors of the liver.Semantic proximity Read ↗

Protocol for generation of humanized HCC mouse model and cancer-driver mutations using CRISPR-Cas9.Semantic proximity Read ↗

Cooperation between MYC and β-catenin in liver tumorigenesis requires Yap/TazSemantic proximity Read ↗

Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis.Semantic proximity Read ↗

MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilitiesSemantic proximity Read ↗

Establishment of liver tumor cell lines from atherogenic and high fat diet fed hepatitis C virus transgenic mice.Semantic proximity Read ↗

The Hippo effector TAZ cooperates with oncogenic β-catenin in experimental and human hepatoblastoma developmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.